These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 34118353)

  • 1. Serum HMGB1 associates with liver disease and predicts readmission and mortality in patients with alcohol use disorder.
    Vannier AGL; Wardwell B; Fomin V; PeBenito A; Wolczynski N; Piaker S; Kedrin D; Chung RT; Schaefer E; Goodman R; Patel SJ; Luther J
    Alcohol; 2021 Sep; 95():37-43. PubMed ID: 34118353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High mobility group box-1 (HMGB1) participates in the pathogenesis of alcoholic liver disease (ALD).
    Ge X; Antoine DJ; Lu Y; Arriazu E; Leung TM; Klepper AL; Branch AD; Fiel MI; Nieto N
    J Biol Chem; 2014 Aug; 289(33):22672-22691. PubMed ID: 24928512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lifetime drinking history in patients with alcoholic liver disease and patients with alcohol use disorder without liver disease.
    Nielsen JK; Olafsson S; Bergmann OM; Runarsdottir V; Hansdottir I; Sigurdardottir R; Björnsson ES
    Scand J Gastroenterol; 2017; 52(6-7):762-767. PubMed ID: 28276826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum keratin 18-M65 levels detect progressive forms of alcohol-associated liver disease in early noncirrhotic stages.
    Maccioni L; Horsmans Y; Leclercq I; Schnabl B; Stärkel P
    Alcohol Clin Exp Res (Hoboken); 2023 Jun; 47(6):1079-1087. PubMed ID: 37060262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum Fibroblast Growth Factor-21 Discriminates Between Decompensated Alcohol-Associated Cirrhosis and Severe Alcohol-Associated Hepatitis.
    McLean Diaz P; Vannier A; Joshi AD; Mahle RE; Przybyszewski EM; Corey K; Chung RT; Luther J; Goodman RP; Schaefer EAK
    Clin Transl Gastroenterol; 2023 Jun; 14(6):e00585. PubMed ID: 36972232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Theragnostic Efficacy of K18 Response in Alcohol Use Disorder with Clinically Significant Fibrosis Using Gut-Liver Axis.
    Sagaram M; Parthasarathy R; Condon SL; Closson CF; Kong M; Schwandt ML; Jophlin LL; Feng W; Barve AJ; Vatsalya V
    Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying Alcohol Use Disorder in Patients With Cirrhosis Reduces 30-Days Readmission Rate.
    Singal AK; DiMartini A; Leggio L; Arab JP; Kuo YF; Shah VH
    Alcohol Alcohol; 2022 Sep; 57(5):576-580. PubMed ID: 35544033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and Progression of Alcohol-Associated Liver Disease After Medical Therapy for Alcohol Use Disorder.
    Vannier AGL; Shay JES; Fomin V; Patel SJ; Schaefer E; Goodman RP; Luther J
    JAMA Netw Open; 2022 May; 5(5):e2213014. PubMed ID: 35594048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treating Alcohol Use Disorder in Patients with Alcohol-Associated Liver Disease: Controversies in Pharmacological Therapy.
    Tarli C; Mirijello A; Addolorato G
    Semin Liver Dis; 2022 May; 42(2):138-150. PubMed ID: 35292951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alcohol use disorder and the liver.
    Buchanan R; Sinclair JMA
    Addiction; 2021 May; 116(5):1270-1278. PubMed ID: 32710592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic review with meta-analysis on transplantation for alcohol-related liver disease: Very low evidence of improved outcomes.
    Shen NT; Londono C; Gold S; Wu A; Mages KC; Brown RSJ
    World J Gastroenterol; 2019 Apr; 25(13):1628-1639. PubMed ID: 30983822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum IgA levels and IgA/IgG ratio in Alcoholic Liver Disease.
    BhatB NM
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gut microbiota compositional and functional fingerprint in patients with alcohol use disorder and alcohol-associated liver disease.
    Addolorato G; Ponziani FR; Dionisi T; Mosoni C; Vassallo GA; Sestito L; Petito V; Picca A; Marzetti E; Tarli C; Mirijello A; Zocco MA; Lopetuso LR; Antonelli M; Rando MM; Paroni Sterbini F; Posteraro B; Sanguinetti M; Gasbarrini A
    Liver Int; 2020 Apr; 40(4):878-888. PubMed ID: 31951082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salvianic acid A alleviates chronic alcoholic liver disease by inhibiting HMGB1 translocation via down-regulating BRD4.
    Lan Y; Yan R; Shan W; Chu J; Sun R; Wang R; Zhao Y; Wang Z; Zhang N; Yao J
    J Cell Mol Med; 2020 Aug; 24(15):8518-8531. PubMed ID: 32596881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of alcohol use disorder in patients with cirrhosis in the setting of liver transplantation.
    Arab JP; Izzy M; Leggio L; Bataller R; Shah VH
    Nat Rev Gastroenterol Hepatol; 2022 Jan; 19(1):45-59. PubMed ID: 34725498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indications for and outcomes of liver transplantation in patients with alcohol-associated liver disease.
    Phillips PK; Caldis MW; Hristov AD; Lee AS; Lucey MR
    Minerva Gastroenterol Dietol; 2018 Jun; 64(2):126-137. PubMed ID: 29243894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alcohol use disorder treatment and outcomes among hospitalized adults with alcoholic hepatitis.
    Winters AC; May FP; Wang Y; Shao P; Yang L; Patel AA
    Drug Alcohol Depend Rep; 2021 Dec; 1():100004. PubMed ID: 36843910
    [No Abstract]   [Full Text] [Related]  

  • 18. Substance use disorder is associated with alcohol-associated liver disease in patients with alcohol use disorder.
    Vannier AGL; Fomin V; Chung RT; Patel SJ; Schaefer E; Goodman RP; Luther J
    Gastro Hep Adv; 2022; 1(3):403-408. PubMed ID: 35474707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Changing Epidemiology of Alcohol-Associated Liver Disease: Gender, Race, and Risk Factors.
    Anouti A; Mellinger JL
    Semin Liver Dis; 2023 Feb; 43(1):50-59. PubMed ID: 36529138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of alcohol misuse in patients with liver diseases.
    Peng JL; Patel MP; McGee B; Liang T; Chandler K; Tayarachakul S; O'Connor S; Liangpunsakul S
    J Investig Med; 2017 Mar; 65(3):673-680. PubMed ID: 27940551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.